This clinical trial is focused on studying atopic dermatitis, a condition that causes the skin to become red, itchy, and inflamed. The study will evaluate a treatment called GSK1070806, which is a type of medication known as a humanised IgG1 kappa monoclonal antibody against interleukin 18. This medication is given as an injection under the skin and is being tested to see how safe and effective it is for people with moderate to severe atopic dermatitis.

The purpose of the study is to understand the long-term safety of different doses and schedules of GSK1070806 in participants who have already completed earlier related studies. Participants will receive either the study medication or a placebo, which is a substance with no active drug. The study will monitor participants over a period of time to observe any side effects and to see how well the treatment works in reducing the symptoms of atopic dermatitis.

Throughout the study, participants will have regular check-ups to assess their skin condition and overall health. The study aims to gather information on any adverse events, which are unwanted effects that may occur during treatment, and to track improvements in skin condition using specific measures. This information will help determine the potential benefits and risks of using GSK1070806 for treating atopic dermatitis.